Versant’s Pipeline raises $30M series B for regenerative therapies

Aiming to enter the clinic before year end, Versant-backed Pipeline Therapeutics raised $30 million in a series B led by new investor Sectoral Asset Management.

Versant Ventures also participated in the round, along with new investors Cleva Pharma Capital, RBV Capital and Hadean Ventures...